Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
IPSC Stock Summary
Top 10 Correlated ETFs
In the News
Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study
Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas.
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at 9:00 AM ET.
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.53 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.66 per share a year ago.
Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., ad-interim Chief Executive Officer, will participate in a fireside chat at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on Monday, April 24, 2023 at 10:30 AM ET.
Century Therapeutics to Present at Upcoming Investor Conferences
PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in the following investor conferences:
Century Therapeutics to Present at Upcoming Investor Conferences
PHILADELPHIA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in the following investor conferences in February:
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.
5 Best and Worst Performing Small-Cap Stocks in Dec 2022
Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.
After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
IPSC Financial details
IPSC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
|Revenue per share||0||0||0||0.09|
|Net income per share||-5.91||-1.31||-2.96||-2.27|
|Operating cash flow per share||-0.39||-0.99||-2.75||0.24|
|Free cash flow per share||-0.45||-1.22||-4.14||-0.29|
|Cash per share||1.96||1.81||6.88||5.46|
|Book value per share||-2.21||-2.55||12.23||5.24|
|Tangible book value per share||-2.21||-2.77||12.23||5.24|
|Share holders equity per share||-2.21||-2.55||12.23||5.24|
|Interest debt per share||0||0.52||0.81||0.87|
|Price to sales ratio||0||0||0||56.99|
|EV to sales||0||0||0||50.29|
|Enterprise value over EBITDA||-48.77||-20.16||-5.09||-2.16|
|EV to operating cash flow||-56.03||-22.99||-5.4||18.6|
|EV to free cash flow||-48.63||-18.57||-3.59||-15.79|
|Free cash flow yield||-0.02||-0.05||-0.26||-0.06|
|Debt to equity||0||-0.2||0.06||0.16|
|Debt to assets||0||0.2||0.06||0.1|
|Net debt to EBITDA||2.37||0.12||0.35||0.29|
|Sales general and administrative to revenue||0||0||0||6.13|
|Research and developement to revenue||0||0||0||20.61|
|Intangibles to total assets||0||0.09||0||0|
|Capex to operating cash flow||0.15||0.24||0.51||-2.18|
|Capex to revenue||0||0||0||-5.89|
|Capex to depreciation||-9.88||-7.01||-12||-3.63|
|Stock based compensation to revenue||0||0||0||2.05|
|Return on tangible assets||-2.71||-0.56||-0.22||-0.27|
|Tangible asset value||-91.86M||-115.8M||396.24M||302.74M|
|Net current asset value||-98.63M||-134.39M||187.02M||135.92M|
|Days sales outstanding||0||0||0||54.76|
|Days payables outstanding||0||0||0||0|
|Days of inventory on hand||0||0||0||0|
|Capex per share||-0.06||-0.24||-1.39||-0.53|
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
|Revenue per share||0.04||0.01||0.03||0||0|
|Net income per share||-0.53||-0.55||-0.53||-0.56||-0.55|
|Operating cash flow per share||-0.42||-0.4||-0.5||-0.32||-0.23|
|Free cash flow per share||-0.59||-0.51||-0.58||-0.4||-0.28|
|Cash per share||6.14||5.46||4.29||2.64||2.85|
|Book value per share||5.7||5.24||4.73||4.18||3.69|
|Tangible book value per share||5.7||5.24||4.73||4.18||3.69|
|Share holders equity per share||5.7||5.24||4.73||4.18||3.69|
|Interest debt per share||0.82||0.86||0.88||0.71||0.8|
|Price to sales ratio||257.81||568.69||118.24||1.89K||803.35|
|EV to sales||228.99||501.8||97.68||1.66K||737.33|
|Enterprise value over EBITDA||-18.42||-9.18||-5.67||-6.66||-3.88|
|EV to operating cash flow||-21.01||-11.41||-5.75||-8.56||-8|
|EV to free cash flow||-14.96||-8.96||-4.91||-6.94||-6.45|
|Free cash flow yield||-0.06||-0.1||-0.17||-0.13||-0.14|
|Debt to equity||0.14||0.16||0.19||0.17||0.22|
|Debt to assets||0.09||0.1||0.11||0.1||0.12|
|Net debt to EBITDA||2.32||1.22||1.19||0.91||0.35|
|Sales general and administrative to revenue||3.63||15.82||5.18||83.12||60.72|
|Research and developement to revenue||11.64||49.11||14.48||229.57||153.97|
|Intangibles to total assets||0||0||0||0||0|
|Capex to operating cash flow||0.4||0.27||0.17||0.23||0.24|
|Capex to revenue||-4.41||-12.03||-2.9||-45.45||-22.06|
|Capex to depreciation||-3.54||-2.21||-1.72||-1.39||-0.97|
|Stock based compensation to revenue||1.25||5.24||2.21||33.18||26.88|
|Return on tangible assets||-0.06||-0.07||-0.07||-0.08||-0.08|
|Tangible asset value||330.21M||302.74M||277.18M||247.57M||219.23M|
|Net current asset value||180.1M||135.92M||76.88M||-8.31M||-4.62M|
|Days sales outstanding||14.73||134.74||76.66||1.55K||1.01K|
|Days payables outstanding||0||0||0||0||0|
|Days of inventory on hand||0||0||0||0||0|
|Capex per share||-0.17||-0.11||-0.09||-0.08||-0.05|
IPSC Frequently Asked Questions
What is Century Therapeutics, Inc. stock symbol ?
Century Therapeutics, Inc. is a US stock , located in Philadelphia of Pa and trading under the symbol IPSC
Is Century Therapeutics, Inc. buy or a sell ?
4 stock analysts have 4 predictions with a medium analyst target price of $21.25. The lowest prediction is $14 and the highest is $27
What is IPSC stock prediction ?
What is Century Therapeutics, Inc. stock quote today ?
Century Therapeutics, Inc. stock price is $2.38 today.
Is Century Therapeutics, Inc. stock public?
Yes, Century Therapeutics, Inc. is a publicly traded company.